Paricalcitol
- TRADE NAME: Zemplar (AbbVie)
- INDICATIONS: Secondary hyperparathyroidism associated with renal failure
- CLASS: Vitamin D receptor agonist
- HALF-LIFE: 4–7 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Bile acid sequestrants, Cardiac glycosides, Conivaptan, Danazol, Darunavir, Delavirdine, Digitalis (with overdose of paricalcitol), Digoxin, Ergocalciferol, Indinavir, Ketoconazole, Orlistat, Orlistat, Strong CYP3A4 inhibitors, Sucralfate, Telithromycin, Thiazide diuretics, Tocilizumab, Voriconazole
PREGNANCY CATEGORY: C
Contra-indicated in patients with evidence of vitamin D toxicity or hypercalcemia.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of paricalcitol in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/13/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric